title: [Vedolizumab (Entyvio®) for the treatment of inflammatory bowel diseases].
abstract: Anti-TNF agents are highly effective in treating inflammatory bowel diseases, but loss of response and side-effects leading to drug interruption are often reported. New molecules are needed to treat these patients. Vedolizumab is a fully humanized anti-body inhibiting the migration of circulating lymphocytes to the gut by binding the integrin α4β7. In ulcerative colitis, clinical response, remission and mucosal healing were observed at 6 weeks in 47%, 17% and 40% of the patients, respectively. The maintenance study demonstrated 42% and 52% of clinical remission and response at week 52. In Crohn's disease, clinical response and remission were respectively observed in 15% and 31% of the patients at 6 weeks. Clinical remission at week 52 was 39%. The time to clinical response was longer in patients who had failed anti-TNF. The safety profile is excellent with the same proportion of side-effects in the placebo and in the treated groups. The most frequently reported adverse events were pharyngitis and headaches.
authors.forename: C
authors.initials: C
authors.lastname: Van Kemseke
authors.forename: E
authors.initials: E
authors.lastname: Louis
authors.forename: C
authors.initials: C
authors.lastname: Reenaers
mesh_terms: D061067:Antibodies, Monoclonal, Humanized / Q000494:pharmacology*; D002986:Clinical Trials as Topic; D005765:Gastrointestinal Agents / Q000494:pharmacology*; D006801:Humans; D015212:Inflammatory Bowel Diseases / Q000188:drug therapy*
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D005765:Gastrointestinal Agents; C543529:vedolizumab